Treatment with irbesartan or atenolol improves endothelial function in essential hypertension
作者:
Bengt von zur Mühlen,
Thomas Kahan,
Anders Hägg,
Jonas Millgård,
Lars Lind,
期刊:
Journal of Hypertension
(OVID Available online 2001)
卷期:
Volume 19,
issue 10
页码: 1813-1818
ISSN:0263-6352
年代: 2001
出版商: OVID
关键词: endothelium;nitric oxide;angiotensin II antagonist;hypertension;human;blood flow
数据来源: OVID
摘要:
ObjectivesTo investigate if antihypertensive treatment could improve endothelium-dependent vasodilatation in hypertensive patients, and whether the angiotensin II subtype-1 (AT1)-receptor antagonist irbesartan and the β1-receptor antagonist atenolol would differ in this respect.Subjects and methodsThirty-four patients (28 men and six women) with mild-to-moderate essential hypertension (diastolic blood pressure 90–120 mmHg) were randomized to once daily 150–300 mg irbesartan or 50–100 mg atenolol in a double-blind fashion, preceded by a placebo run-in period. Forearm blood flow (FBF) was assessed by venous occlusion plethysmography during local intra-arterial infusions of methacholine and sodium nitroprusside, to evaluate endothelium-dependent and endothelium-independent vasodilatation, respectively. Measurements of FBF were undertaken at the end of the run-in placebo period and repeated after 3 months of active antihypertensive treatment.ResultsIrbesartan and atenolol induced a similar decline in blood pressure (from 171/107 to 158/98 mmHg,P< 0.05), and improved endothelium-dependent vasodilatation (e.g. an increase in FBF response to 4 μg/min methacholine from 325±29% to 411±41%,P<0.05), with no difference between the two study drugs. No significant changes in endothelium-independent vasodilatation were induced by irbesartan or by atenolol.ConclusionsThe present study shows that 3 months of antihypertensive therapy with irbesartan or atenolol improves endothelium-dependent vasodilatation.
点击下载:
PDF
(193KB)
返 回